Axsome (AXSM) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 07/11/23
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in AdultsGlobeNewsWire • 07/07/23
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common StockGlobeNewsWire • 06/30/23
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common StockGlobeNewsWire • 06/28/23
This Stock Crushed the Market Last Year. Here's Why It Could Do That Again.The Motley Fool • 06/16/23
Axsome Therapeutics Expects Up To $11.5 Billion In Peak Sales, Wallops Analysts' ForecastsInvestors Business Daily • 06/14/23
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingGlobeNewsWire • 05/30/23